𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A double-blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil®) with fluconazole (Diflucan®) in the treatment of onychomycosis

✍ Scribed by V. Havu; H. Heikkilä; K. Kuokkanen; M. Nuutinen; T. Rantanen; S. Saari; S. Stubb; R. Suhonen; K. Turjanmaa

Publisher
John Wiley and Sons
Year
2000
Tongue
English
Weight
316 KB
Volume
142
Category
Article
ISSN
0007-0963

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

L.I.ON. Study: efficacy and tolerability
L.I.ON. Study: efficacy and tolerability of continuous terbinafine (Lamisil®) compared to intermittent itraconazole in the treatment of toenail onychomycosis
✍ Sigurgeirsson; Billstein; Rantanen; Ruzicka; Di Fonzo; Vermeer; Goodfield; Evans 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 415 KB

We undertook a prospective, randomised, double-blind, double-dummy, multicentre, parallel-group study to compare the efficacy and tolerability of continuous terbinafine (Lamisil) with intermittent itraconazole (Sporanox) in the treatment of toenail onychomycosis. A total of 496 patients (age range 1

A multicentre (double-blind) comparative
A multicentre (double-blind) comparative study to assess the safety and efficacy of fluconazole and griseofulvin in the treatment of tinea corporis and tinea cruris
✍ J. FAERGEMANN; N.J. MÖRK; A. HAGLUND; T. ÖDEGÀRD 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 277 KB

In a double-blind, parallel group study we compared fluconazole 150 mg once weekly with griseofulvin 500 mg once daily for 4-6 weeks in the treatment of tinea corporis or tinea cruris. Eighty-four of 114 patients (74%) (39% after 3 weeks) were clinically cured in the fluconazole group compared with

A randomized, double-blind study compari
A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis
✍ Koo; FOR THE OLP302 STUDY GROUP 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 787 KB

This study compared the efficacy, safety and optimal dose of two formulations of cyclosporin, Sandimmun and Neoral, in patients with severe, chronic plaque-type psoriasis. Patients were randomized on a 1:1 basis to 24 weeks of treatment with Neoral (n = 152) or Sandimmun (n = 157). The starting dose

A double blind, randomized clinical tria
A double blind, randomized clinical trial assessing the efficacy and safety of augmenting standard antidepressant therapy with nimodipine in the treatment of ‘vascular depression’
✍ Fernando E. Taragano; Ricardo Allegri; Augusto Vicario; Pablo Bagnatti; Constant 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 1 views

## Abstract ## Background ‘Vascular depression’ may be caused by cerebrovascular disease. Calcium channel blockers, which are putative treatments for cerebrovascular disease, might be expected to improve depression reduction and to prevent recurrence of depression in this patient population. This

A double-blind comparison of the efficac
A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia
✍ Cornelius L. E. Katona; Brian N. Hunter; Julia Bray 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 150 KB 👁 2 views

Objectives. To compare the ecacy of paroxetine and imipramine prospectively in patients with coexisting depression and dementia. Methods. An 8-week, double-blind, parallel group trial comparing paroxetine 20±40 mg/day with imipramine 50±100 mg/day in 198 patients aged 60 years or over with a Montgo

Efficacy and safety of leflunomide in th
Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multinational, double-blind, randomized, placebo-controlled clinical trial
✍ J. Peter Kaltwasser; Peter Nash; Dafna Gladman; Cheryl F. Rosen; Frank Behrens; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB 👁 2 views

## Abstract ## Objective Current treatment options for psoriatic arthritis (PsA) are limited. Leflunomide, an oral pyrimidine synthesis inhibitor, is highly effective in the treatment of rheumatoid arthritis, and small studies have suggested similar efficacy in PsA. We undertook this double‐blind,